As Chief Commercial Officer at Freenome, Michael leads all aspects of Freenome’s commercial strategy and operations, including marketing, sales, market development, market access, and client services.
Prior to Freenome, Michael spent two decades at Genentech, working across diverse therapeutic categories and functional leadership capacities. Most recently, he served as the US Head for Alzheimer’s Disease. Additionally, Michael served as the US Head for Avastin, Herceptin, and Rituxan. Michael also led the Biomarker Testing Team, eMarketing Department and worked in numerous managed care, marketing, and field leadership roles. Before his time at Genentech, Michael worked for Deloitte.
Michael holds a BS in Business Administration from the Eller College of Management at the University of Arizona.